Correction: HLA Class I and Class II Associations with ESRD in Saudi Arabian Population.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Association between human leukocyte antigen (HLA) and end-stage renal disease (ESRD): a meta-analysis.PeerJ · 2023
   Pooled it
2. Determination of HLA Tissue Type According to the Etiology of Patients with Chronic Renal Failure.Medeniyet medical journal · 2024
   Article
3. Associations between end stage renal disease and HLA polymorphisms in the Guangxi Zhuang population.Scientific reports · 2024
   Article
4. Relevance of HLA gene polymorphisms in Romanian patients with chronic renal insufficiency undergoing renal transplantation.Journal of clinical laboratory analysis · 2021
   Article
5. Revisiting the association between human leukocyte antigen and end-stage renal disease.PloS one · 2020
   Article

Corrections and comments

• Erratum for
  HLA class I and class II associations with ESRD in Saudi Arabian population.2014

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract